No Data
OKYO Pharma's Urcosimod Selected for Presentation at ARVO 2026 Annual Meeting Following Positive Phase 2a Trial Results for Neuropathic Corneal Pain Treatment
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday
Piper Sandler Initiates OKYO Pharma(OKYO.US) With Buy Rating, Announces Target Price $7
New Analyst Forecast: $OKYO Given $7 Price Target
Express News | OKYO Pharma Ltd : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $7